These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 33310017)

  • 1. The ACE2-binding Interface of SARS-CoV-2 Spike Inherently Deflects Immune Recognition.
    Hattori T; Koide A; Noval MG; Panchenko T; Romero LA; Teng KW; Tada T; Landau NR; Stapleford KA; Koide S
    J Mol Biol; 2021 Feb; 433(3):166748. PubMed ID: 33310017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ACE2-binding interface of SARS-CoV-2 Spike inherently deflects immune recognition.
    Hattori T; Koide A; Panchenko T; Romero LA; Teng KW; Tada T; Landau NR; Koide S
    bioRxiv; 2020 Nov; ():. PubMed ID: 33173869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
    Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Whaley RE; Singh S; Boeckh M; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L
    Immunity; 2020 Jul; 53(1):98-105.e5. PubMed ID: 32561270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana.
    Rattanapisit K; Shanmugaraj B; Manopwisedjaroen S; Purwono PB; Siriwattananon K; Khorattanakulchai N; Hanittinan O; Boonyayothin W; Thitithanyanont A; Smith DR; Phoolcharoen W
    Sci Rep; 2020 Oct; 10(1):17698. PubMed ID: 33077899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
    Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
    Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.
    Bertoglio F; Meier D; Langreder N; Steinke S; Rand U; Simonelli L; Heine PA; Ballmann R; Schneider KT; Roth KDR; Ruschig M; Riese P; Eschke K; Kim Y; Schäckermann D; Pedotti M; Kuhn P; Zock-Emmenthal S; Wöhrle J; Kilb N; Herz T; Becker M; Grasshoff M; Wenzel EV; Russo G; Kröger A; Brunotte L; Ludwig S; Fühner V; Krämer SD; Dübel S; Varani L; Roth G; Čičin-Šain L; Schubert M; Hust M
    Nat Commun; 2021 Mar; 12(1):1577. PubMed ID: 33707427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
    Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R
    Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2.
    Passariello M; Gentile C; Ferrucci V; Sasso E; Vetrei C; Fusco G; Viscardi M; Brandi S; Cerino P; Zambrano N; Zollo M; De Lorenzo C
    Sci Rep; 2021 May; 11(1):11046. PubMed ID: 34040046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2.
    Bracken CJ; Lim SA; Solomon P; Rettko NJ; Nguyen DP; Zha BS; Schaefer K; Byrnes JR; Zhou J; Lui I; Liu J; Pance K; ; Zhou XX; Leung KK; Wells JA
    Nat Chem Biol; 2021 Jan; 17(1):113-121. PubMed ID: 33082574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes.
    Noy-Porat T; Makdasi E; Alcalay R; Mechaly A; Levy Y; Bercovich-Kinori A; Zauberman A; Tamir H; Yahalom-Ronen Y; Israeli M; Epstein E; Achdout H; Melamed S; Chitlaru T; Weiss S; Peretz E; Rosen O; Paran N; Yitzhaki S; Shapira SC; Israely T; Mazor O; Rosenfeld R
    Nat Commun; 2020 Aug; 11(1):4303. PubMed ID: 32855401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection.
    Carlos AJ; Ha DP; Yeh DW; Van Krieken R; Tseng CC; Zhang P; Gill P; Machida K; Lee AS
    J Biol Chem; 2021; 296():100759. PubMed ID: 33965375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library.
    Bell BN; Powell AE; Rodriguez C; Cochran JR; Kim PS
    Protein Sci; 2021 Apr; 30(4):716-727. PubMed ID: 33586288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines.
    Guo Y; He W; Mou H; Zhang L; Chang J; Peng S; Ojha A; Tavora R; Parcells MS; Luo G; Li W; Zhong G; Choe H; Farzan M; Quinlan BD
    mBio; 2021 May; 12(3):. PubMed ID: 33975938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular insights into the binding variance of the SARS-CoV-2 spike with human, cat and dog ACE2 proteins.
    Zang Y; Li X; Zhao Y; Wang H; Hao D; Zhang L; Yang Z; Yuan X; Zhang S
    Phys Chem Chem Phys; 2021 Jun; 23(24):13752-13759. PubMed ID: 34132301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plant-Produced Glycosylated and In Vivo Deglycosylated Receptor Binding Domain Proteins of SARS-CoV-2 Induce Potent Neutralizing Responses in Mice.
    Mamedov T; Yuksel D; Ilgın M; Gurbuzaslan I; Gulec B; Yetiskin H; Uygut MA; Islam Pavel ST; Ozdarendeli A; Mammadova G; Say D; Hasanova G
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a neutralizing antibody that recognizes a loop region adjacent to the receptor-binding interface of the SARS-CoV-2 spike receptor-binding domain.
    Anzai I; Fujita J; Ono C; Kosaka Y; Miyamoto Y; Shichinohe S; Takada K; Torii S; Taguwa S; Suzuki K; Makino F; Kajita T; Inoue T; Namba K; Watanabe T; Matsuura Y
    Microbiol Spectr; 2024 Apr; 12(4):e0365523. PubMed ID: 38415660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape.
    Yang L; Li J; Guo S; Hou C; Liao C; Shi L; Ma X; Jiang S; Zheng B; Fang Y; Ye L; He X
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.